- Galderma completed pCPA negotiations for Nemluvio (nemolizumab), advancing access for patients ≥12 years with moderate-to-severe atopic dermatitis (AD) and adults with moderate-to-severe prurigo nodularis (PN) inadequately controlled with topical therapies.
- Nemluvio is the first approved monoclonal antibody targeting IL-31 receptor alpha, blocking IL-31 signaling involved in itch, inflammation, skin-barrier dysfunction in AD, and fibrosis in PN.
- The milestone follows CDA-AMC’s March 2026 recommendation to reimburse Nemluvio with conditions for eligible patients with moderate-to-severe AD and PN, alongside a positive INESSS indication for PN in February 2026.
- Galderma will continue working with public drug plans and the dermatology community to support access to Nemluvio for eligible Canadians as the reimbursement process progresses.
Takeaways:
Completing pCPA negotiations is a key step toward public reimbursement for Nemluvio in Canada, which—once provincial/territorial drug plans list it—should materially expand access for patients ≥12 with moderate‑to‑severe atopic dermatitis and adults with prurigo nodularis who are inadequately controlled on topicals. As the first IL‑31Rα inhibitor (and the first publicly reimbursed option for prurigo nodularis in Canada), Nemluvio can carve out a differentiated niche versus existing AD biologics/JAK inhibitors, supporting Galderma’s dermatology franchise in a PN market projected to grow ~23% CAGR and an AD biologic segment where payers are prioritizing itch‑focused, steroid‑sparing therapies.
Source: CA Newswire
